← Back to Adaptimmune Therapeutics plc Stock
Adaptimmune Therapeutics plc (ADAPY) News
Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.
By Michael Kim
Adaptimmune Therapeutics (ADAP) has provided an update. Adaptimmune Therapeutics plc has updated its executive severance policy to offer more gener…
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysisInterim analysis data reinforces the p…
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, is presenting data from its pivotal IGNYTE-ESO trial of lete-cel (letetresgene autoleucel), an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual meeting. Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center will present "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" in an oral session at 11:30 a.m.
Shares of Zscaler, Inc . (NASDAQ: ZS ) rose sharply in today''s pre-market trading after the company reported better-than-expected third-quarter earnings. Zscaler said third-quarter revenue increased 32% year-over-year to $553.2 million, which beat the consensus estimate of $535.906 million, according to Benzinga Pro . The company reported quarterly adjusted earnings of 88 cents per share, beating analyst estimates of 66 cents per share. Zscaler shares jumped 17.5% to $184.12 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Nuburu, Inc . (NYSE: BURU ) rose 71.9% to $0.2750 in today''s pre-market trading after falling around 12% on Thursday. XChange Tec Inc (NASDAQ: XHG ) shares gained 64.9% to $1.13 in pre-market trading after dipping 15% on Thursday. Novo Integrated Sciences, Inc . (NASDAQ: NVOS ) gained 49.9% to $0.6760 in pre-market trading following HSBC‘s confirmation of a $78 million Standby Letter of Credit. Adaptimmune Therapeutics plc (NASDAQ: ADAP ) gained 29.7% to $1.31 in pre-market trading after the company and Galapagos entered a clinical collaboration to license Adaptimmune’s uza-cel in in head & neck …
Adaptimmune Therapeutics (ADAP) has issued an announcement. Adaptimmune Limited and Galapagos NV have embarked on a promising collaboration, initia…
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
Adaptimmune Therapeutics (NASDAQ: ADAP ) just reported results for the first quarter of 2024. Adaptimmune Therapeutics reported earnings per share of -18 cents. This was below the analyst estimate for EPS of -10 cents. The company reported revenue of $5.68 million. This was 47.08% worse than the analyst estimate for revenue of $10.73 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.